IOVA Iovance Biotherapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: IOVA

Price (delayed)

$9.25

Market cap

$2.59B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.8

Enterprise value

$2.53B

Iovance Biotherapeutics aims to improve patient care by making T cell-based immunotherapies broadly accessible for the treatment of patients with solid tumors and blood cancers. Tumor infiltrating lymphocyte (TIL) therapy ...

Highlights
IOVA's revenue has soared by 60% QoQ
The EPS has grown by 25% YoY and by 4.8% from the previous quarter
The company's quick ratio fell by 40% YoY but it rose by 39% QoQ
The gross profit has plunged by 68% from the previous quarter
Iovance Biotherapeutics's debt has increased by 11% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.iovance.com
Peers: NWBO

Key stats

What are the main financial stats of IOVA
Market
Shares outstanding
279.83M
Market cap
$2.59B
Enterprise value
$2.53B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
3.8
Price to sales (P/S)
1,293.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,329.94
Earnings
Revenue
$1.9M
EBIT
-$454.53M
EBITDA
-$417.19M
Free cash flow
-$405.08M
Per share
EPS
-$1.8
Free cash flow per share
-$1.52
Book value per share
$2.43
Revenue per share
$0.01
TBVPS
$2.16
Balance sheet
Total assets
$869.83M
Total liabilities
$189.81M
Debt
$84.37M
Equity
$680.02M
Working capital
$302.32M
Liquidity
Debt to equity
0.12
Current ratio
4.63
Quick ratio
4.36
Net debt/EBITDA
0.13
Margins
EBITDA margin
-21,911.4%
Gross margin
-846.2%
Net margin
-23,615.7%
Operating margin
-24,549.6%
Efficiency
Return on assets
-55.2%
Return on equity
-71.5%
Return on invested capital
-142.9%
Return on capital employed
-57.8%
Return on sales
-23,872.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IOVA stock price

How has the Iovance Biotherapeutics stock price performed over time
Intraday
-1.91%
1 week
16.21%
1 month
14.06%
1 year
31.21%
YTD
13.78%
QTD
15.34%

Financial performance

How have Iovance Biotherapeutics's revenue and profit performed over time
Revenue
$1.9M
Gross profit
-$16.11M
Operating income
-$467.43M
Net income
-$449.64M
Gross margin
-846.2%
Net margin
-23,615.7%
The gross profit has plunged by 68% from the previous quarter
IOVA's revenue has soared by 60% QoQ
Iovance Biotherapeutics's net margin has increased by 37% from the previous quarter
The operating margin is up by 37% from the previous quarter

Growth

What is Iovance Biotherapeutics's growth rate over time

Valuation

What is Iovance Biotherapeutics stock price valuation
P/E
N/A
P/B
3.8
P/S
1,293.35
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,329.94
The EPS has grown by 25% YoY and by 4.8% from the previous quarter
IOVA's price to book (P/B) is 32% less than its 5-year quarterly average of 5.7 but 11% more than its last 4 quarters average of 3.5
IOVA's equity is up by 16% since the previous quarter
IOVA's revenue has soared by 60% QoQ
The price to sales (P/S) is 56% lower than the last 4 quarters average of 2975.5

Efficiency

How efficient is Iovance Biotherapeutics business performance
Iovance Biotherapeutics's ROIC has decreased by 41% YoY but it has increased by 12% from the previous quarter
The ROS has grown by 37% from the previous quarter
The ROE is up by 12% year-on-year
The return on assets has increased by 11% year-on-year

Dividends

What is IOVA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IOVA.

Financial health

How did Iovance Biotherapeutics financials performed over time
The current ratio has soared by 66% from the previous quarter but it has decreased by 37% YoY
The company's quick ratio fell by 40% YoY but it rose by 39% QoQ
Iovance Biotherapeutics's debt is 88% less than its equity
IOVA's equity is up by 16% since the previous quarter
Iovance Biotherapeutics's debt has increased by 11% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.